In a decision from yesterday the US Supreme Court has paused judgement. That translates into the FDA directions about the drug doesn’t make it a drug of choice in the near future. From the US Supreme Court’s judgement the final decision is not yet from the highest authority in the land.
As a result, the decision could potentially benefit many (? but, how many is still not clear is unanswered) young women and girls seeking abortion. The general opinion is that the decision of the US Supreme Court is good. It has not been hasty in banning Mifipristone.
The potency, safety, efficacy of the drug and the side-effects (contraindications) is not ruled out entirely. However, the administration is clear that the US administration will go by the decision whatever the FDA decides.
More other factors are unaddressed by the administration clearly seen that it is not ready yet to answer a few simple questions. Will the drug become a drug of choice in the future?
It is obvious from its answers that whether it will go by the Supreme Court’s decision in the future? As opposed to in the past.
Comments
Post a Comment